Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland

OBJECTIVE: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. METHODS: Retrospective health care record of 61 consecutive HIV treatment-naive...

Descripción completa

Detalles Bibliográficos
Autores principales: Waqas, Sarmad, O’Connor, Mairead, Levey, Ciara, Mallon, Paddy, Sheehan, Gerard, Patel, Anjali, Avramovic, Gordana, Lambert, John S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084612/
https://www.ncbi.nlm.nih.gov/pubmed/27826447
http://dx.doi.org/10.1177/2050312116675813
Descripción
Sumario:OBJECTIVE: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. METHODS: Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS. RESULTS: The mean initial viral load was 160826.05 copies/mL (range, 79–1,126,617 copies/mL). HIV viral load became non-detectable in 63.9% of patients on dolutegravir within 3 months. In all, 60.7% of patients reported no side effects on dolutegravir; 98.4% of the patients claimed full compliance to their antiretrovirals. CONCLUSION: Dolutegravir was found to be efficacious and well tolerated in HIV-infected treatment-naive patients.

Ejemplares similares